Repeat Revascularization With Drug Eluting versus Bare Metal Stents
REFERENCE: American Heart Association Scientific Sessions, Chicago, November 12-15, 2006. Abstract 1948 (C 206) Page: 236, Sunday 12th
OSCAR C MARROQUIN, University of Pittsburgh
Although drug eluting stents reduce the need for repeat revascularization, the timing of stent failure is less predictable than with bare metal stents. This is the finding of a study using data from the National Heart Lung and Blood Institute Dynamic Registry. Oscar Marroquin told the Chicago conference about the comparison his group has made between different waves of patients having angioplasty before and after the adoption of drug eluting stents.
Are Drug Eluting Stents Really Worth the Money?
REFERENCE: American Heart Association Scientific Sessions, Chicago, November 12-15, 2006. Abstract: 1949 (C207) Sunday page: 236
SANJAY KAUL, Cedars-Sinai Medical Center, Los Angeles
A strategy of unconditional substitution of bare metal with drug eluting stents is not cost-worthy, according to a study from Sanjay Kaul who recommended to delegates at the AHA conference that more selective use of drug eluting stents should be applied in the cath lab.
Cardiac Alllograft Patients: Drug Eluting Stents Better, But Not as Good as Hoped
REFERENCE: American Heart Association Scientific Sessions, Chicago, November 12-15, 2006. Abstract 1957 C215 Sunday page 236
JOSEPH SWEENY, Mount Sinai School of Medicine, New York
The superiority of drug-eluting over bare metal stents has been confirmed among heart transplant patients, but the benefit does not seem to be as great as has been hoped. Joseph Sweeny told AHA delegates what his group found from their study and what the implications might be.
Atrial Fibrilation An Independent Predictor of Mortality. Euro Heart Failure Survey Results: A Retrospective Analysis
American Heart Association Scientific Sessions 2006 November 12-15th Chicago, Illinois. Abstract: 2013 Page 242 Sunday Oral Session
MAXIMO RIVERO-AYERZA, Erasmus Medical Centre, Rotterdam, The Netherlands
Don’t under-estimate new onset atrial fibrillation in your patients admitted with heart failure: so said Maximo Rivero-Ayerza, who’s found a significant contribution of AF to subsequent mortality.